Morbid obesity and non alchoholic liver diseade. Overweight and obesity
Conditions
Interventions
Intervention 1: Intervention group: 500 kcal.day deficit from their normal weight-maintaining caloric intake plus taking 140 mg of Silymarin in tablet form, four times daily, for a total of 560 mg for
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: patients aged between 18 and 65 years morbidly-obese patients candidates for bariatric surgery , BMI above 40 kg/m2 Diagnosis of NAFLD in liver sonography (grades II and III steatosis) with increased levels of liver enzymes aspartate transaminase (AST) and alanine transaminase (ALT) (above 20 mg/dl for women and 30 mg/dl for men)
Exclusion criteria
Exclusion criteria: history of alcohol consumption diabetes mellitus chronic liver disease use of drugs such as statin, fibrate, non-steroidal anti-inflammatory drugs (NSAIDs), positive results for tests of autoimmune hepatitis and virus markers (hepatitis B surface antigen, hepatitis C virus antibody) unwilling to participate in study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Aspartate aminotransferase/alanine aminotransferase ratio. Timepoint: before and after two months of treatment. Method of measurement: Blood sample.;BMI (body mass index). Timepoint: before and after two months of treatment. Method of measurement: scale.;Non alchoholic fatty liver disease. Timepoint: before and after two months of treatment. Method of measurement: Sonography.;Liver fibrosis. Timepoint: before and after two months of treatment. Method of measurement: Fibroscan Metavir. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed Hadi Mirhashemi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed